瑞士制药商罗氏（Roche）德国负责人周一在接受《世界报》采访时表示，由于德国的医疗成本削减政策，该公司正在重新评估未来在德国的所有投资。
Swiss drugmaker Roche is reviewing all future investments in Germany over healthcare cost-cutting policies, the company's Germany chief said in an interview with newspaper Welt that was published on Monday.
罗氏德国负责人丹尼尔·施泰纳斯（Daniel Steiners）表示：“我们目前已暂停在德国的所有未来投资决定。”他补充说，对制药行业而言，政策制定者“近期摧毁了大量信任”。
"We have put all future investment decisions in Germany on hold for the time being," said Daniel Steiners, head of Roche Germany, adding that for the pharmaceutical industry, policy makers had "recently destroyed a lot of trust".
施泰纳斯表示，政策制定者没有着手解决法定医疗保险系统的结构性问题，而是专注于短期节约并给该行业施加额外负担。他还补充说，所谓的“区位条款”本可以免除本土制药企业的制造商折扣，但这只能部分抵消立法带来的负面影响，当前需要的是一项全面战略。
随着德国出台旨在遏制法定医疗保险系统成本快速增长拟议立法，礼来公司（Eli Lilly）早在6月就曾表示，将把其在该国计划中的23亿欧元（约合25.7亿美元）投资减半。
公司发言人对路透社表示，诸如巴伐利亚州彭茨贝格（Penzberg）基地价值超过6亿欧元的扩建等计划投资，并未受到这些评估的影响。
Steiners said that instead of tackling the structural problems of the statutory health insurance system, policy makers are focusing on short-term savings and placing additional burdens on the industry A so-called ‘location clause’, which could exempt domestically producing pharmaceutical companies from manufacturer discounts, would only partially offset the negative effects of the legislation, needed is a comprehensive strategy, he added Following proposed legislation in Germany to cap rapidly growing costs in the statutory health insurance system, Eli Lilly (LLY.N) had in June already said it would halve its planned €2.3 billion ($2.57 billion) investments in the country Planned investments like the more than €600 million expansion of the site in Penzberg, Bavaria, are not impacted by the reviews, a company spokesperson told Reuters